120 related articles for article (PubMed ID: 33554047)
1. Innate RIG-I signaling restores antigen presentation in tumors and overcomes T cell resistance.
Thier B; Paschen A
Cell Stress; 2021 Jan; 5(2):26-28. PubMed ID: 33554047
[TBL] [Abstract][Full Text] [Related]
2. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
[TBL] [Abstract][Full Text] [Related]
3. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
[TBL] [Abstract][Full Text] [Related]
4. HLA Class II Loss and JAK1/2 Deficiency Coevolve in Melanoma Leading to CD4 T-cell and IFNγ Cross-Resistance.
Stupia S; Heeke C; Brüggemann A; Zaremba A; Thier B; Kretz J; Sucker A; Philip M; Zelinskyy G; Ferrone S; Roesch A; Horn S; Hadaschik E; Schadendorf D; Trilling M; Dittmer U; Griewank K; Zhao F; Paschen A
Clin Cancer Res; 2023 Aug; 29(15):2894-2907. PubMed ID: 37199727
[TBL] [Abstract][Full Text] [Related]
5. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.
Thier B; Zhao F; Stupia S; Brüggemann A; Koch J; Schulze N; Horn S; Coch C; Hartmann G; Sucker A; Schadendorf D; Paschen A
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35697379
[TBL] [Abstract][Full Text] [Related]
6. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.
Pérez-Núñez I; Rozalén C; Palomeque JÁ; Sangrador I; Dalmau M; Comerma L; Hernández-Prat A; Casadevall D; Menendez S; Liu DD; Shen M; Berenguer J; Ruiz IR; Peña R; Montañés JC; Albà MM; Bonnin S; Ponomarenko J; Gomis RR; Cejalvo JM; Servitja S; Marzese DM; Morey L; Voorwerk L; Arribas J; Bermejo B; Kok M; Pusztai L; Kang Y; Albanell J; Celià-Terrassa T
Nat Cancer; 2022 Mar; 3(3):355-370. PubMed ID: 35301507
[TBL] [Abstract][Full Text] [Related]
7. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.
Mimura K; Ando T; Poschke I; Mougiakakos D; Johansson CC; Ichikawa J; Okita R; Nishimura MI; Handke D; Krug N; Choudhury A; Seliger B; Kiessling R
Int J Cancer; 2011 Jan; 128(2):390-401. PubMed ID: 20715101
[TBL] [Abstract][Full Text] [Related]
8. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy.
Gong X; Karchin R
Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.
Wickenhauser C; Bethmann D; Kappler M; Eckert AW; Steven A; Bukur J; Fox BA; Beer J; Seliger B
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33557271
[TBL] [Abstract][Full Text] [Related]
10. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
[TBL] [Abstract][Full Text] [Related]
11. RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.
Heidegger S; Kreppel D; Bscheider M; Stritzke F; Nedelko T; Wintges A; Bek S; Fischer JC; Graalmann T; Kalinke U; Bassermann F; Haas T; Poeck H
EBioMedicine; 2019 Mar; 41():146-155. PubMed ID: 30852164
[TBL] [Abstract][Full Text] [Related]
12. Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.
Daßler-Plenker J; Paschen A; Putschli B; Rattay S; Schmitz S; Goldeck M; Bartok E; Hartmann G; Coch C
Int J Cancer; 2019 Apr; 144(7):1645-1656. PubMed ID: 30230526
[TBL] [Abstract][Full Text] [Related]
13. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility antigens and antigen-processing molecules in uveal melanoma.
Krishnakumar S; Abhyankar D; Sundaram AL; Pushparaj V; Shanmugam MP; Biswas J
Clin Cancer Res; 2003 Sep; 9(11):4159-64. PubMed ID: 14519640
[TBL] [Abstract][Full Text] [Related]
15. RIG-I activation is critical for responsiveness to checkpoint blockade.
Heidegger S; Wintges A; Stritzke F; Bek S; Steiger K; Koenig PA; Göttert S; Engleitner T; Öllinger R; Nedelko T; Fischer JC; Makarov V; Winter C; Rad R; van den Brink MRM; Ruland J; Bassermann F; Chan TA; Haas T; Poeck H
Sci Immunol; 2019 Sep; 4(39):. PubMed ID: 31519811
[TBL] [Abstract][Full Text] [Related]
16. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.
Chang CC; Pirozzi G; Wen SH; Chung IH; Chiu BL; Errico S; Luongo M; Lombardi ML; Ferrone S
J Biol Chem; 2015 Oct; 290(44):26562-75. PubMed ID: 26381407
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
[TBL] [Abstract][Full Text] [Related]
18. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
Hargadon KM
Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
[TBL] [Abstract][Full Text] [Related]
19. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
20. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
Pai SI; Jack Lee J; Carey TE; Westra WH; Ferrone S; Moore C; Mosunjac MB; Shin DM; Ferris RL;
Oral Oncol; 2018 Feb; 77():92-97. PubMed ID: 29362132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]